Nothing Special   »   [go: up one dir, main page]

[Validating the Simpson-Angus Extrapyramidal Collateral Symptom Evaluation Scale]

Rev Salud Publica (Bogota). 2006 Jan-Apr;8(1):74-87. doi: 10.1590/s0124-00642006000100007.
[Article in Spanish]

Abstract

Objectives: The study was aimed at validating the Simpson-Angus scale for neuroleptic-induced extrapyramidal syndrome in Colombia, using a Spanish version of the scale.

Methods: The scale was validated in four steps: translating the scale, pilot study, preliminary use for factorial analysis and analysis of validity, reliability and sensitivity to change.

Results: Factorial structure and internal consistency were evaluated in 86 psychiatric inpatients. Test-retest and inter-rater reliability were evaluated in a 15-patient subgroup. Concurrent validity was analysed by simultaneously applying Simpson-Angus and Chouinard scales. Sensitivity to change was evaluated by comparing the scores of two different clinical points in a 20-patient subgroup. Main factor analysis revealed that the scale has a one-dimensional structure; the Glabella tap did not contribute towards total variability of the condition measured for the scale. Test-retest and inter-rater reliability values, concurrent validity and sensitivity to change were good. Correlation estimation scores were above 0.8 and accuracy levels were also good.

Conclusions: The Spanish version of the SA scale, adapted for this study, is suitable for assessing neuroleptic-induced extrapyramidal syndrome; it would be a useful instrument in both clinical practice and research settings in Colombia. However, an important limitation could be its lack of detecting any domain different to that of rigidity.

Publication types

  • Comparative Study
  • Validation Study

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / adverse effects*
  • Basal Ganglia Diseases / chemically induced*
  • Basal Ganglia Diseases / epidemiology
  • Colombia / epidemiology
  • Female
  • Humans
  • Inpatients / psychology
  • Language
  • Male
  • Middle Aged
  • Observer Variation
  • Parkinson Disease, Secondary / chemically induced*
  • Parkinson Disease, Secondary / epidemiology
  • Pilot Projects
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Severity of Illness Index*

Substances

  • Antipsychotic Agents